Je was op zoek naar: kontrollrühmas (Estisch - Engels)

11,0...20,2% kontrollrühmas).
48.7% by day 14 vs placebo 11.0% - 20.2%).

tulemused kontrollrühmas olid sarnased.
the results in the control group were similar.

pp rühmas ja 0, 4% kontrollrühmas.
pci, the incidence of severe haemorrhage was 1.0% for fondaparinux and 0.4% for controls.

Üks kõrvaltoime juht kontrollrühmas oli surmlõppega.
one ild-type event was fatal, and this occurred in a patient receiving placebo.

kontrollrühmas oli vanusevahemik 5,1 kuni 55,7 eluaastat.
the age range in the soc group was 5.1 to 55.7 years.

on keskmise kasvu erikiiruse (µ) keskväärtus kontrollrühmas;
mean value for average specific growth rate (µ) in the control group;

nii katse- kui kontrollrühmas on vähemalt viis analüüsitavat looma.
each treated and control group must include at least five analysable males.

kontrollrühmas ilmnesid spetsiifilised nahakahjustused rohkem kui 80%-l sigadest.
in the control group more than 80% of pigs showed specific skin lesions.

katse- ja kontrollrühmas kasutatakse vähemalt viit emas- ja viit isaslooma.
at least five female and five male animals per experimental and control group are employed.

nii katse- kui kontrollrühmas on mõlemast soost vähemalt viis analüüsitavat looma.
each treated and control group must include at least five analysable animals per sex.

229 siga raviti zuprevoga, kontrollrühmas oli 227 siga, kellele süstiti füsioloogilist lahust.
229 pigs were treated with zuprevo and 227 pigs were untreated controls that received saline.

kontrollrühmas oli 8 sarnaste demograafiliste andmetega uuringus osalejat, kellele manustati 10 mg annus.
eight healthy, demographically matched subjects served as controls and received a 10-mg dose.

40 glivec' i rühmas ja 64, 1% kontrollrühmas (p < 0, 001).
the estimated rate of progression-free survival at 60 months was 83.2% in the glivec arm and 64.1% in the control arm (p < 0.001).

lümfotsüütide arvu langus ilmnes 0,5% patsientidest saksagliptiin- ja 0,4% kontrollrühmas.
decreased lymphocyte counts were reported in 0.5% of saxagliptin-treated patients and 0.4% of placebo-treated patients.

kontrollrühmas ja nädalatel, mil empliciti ei manustatud, manustati ühekordse suukaudse annusena 40 mg deksametasooni nädalas.
in the control group and on weeks without empliciti, dexamethasone 40 mg was administered as a single oral dose weekly.

en tehtud, oli raske hemorraagia esinemissagedus 1, 2% fondapariinuksi vs 1, 5% kontrollrühmas.
fondaparinux patients and in 2.0% of controls.

need kõrvaltoimed esinesid ravirühmades võrdse sagedusega: kaheksa juhtu eviceli saavas rühmas ja kaheksa juhtu kontrollrühmas.
the events were evenly distributed across treatment arms, with 8 each in the evicel and the control groups.

randomiseerimise järgus said trombotsüütide transfusioone 4,7% patsientidest jakavi rühmas ning 4,0% patsientidest kontrollrühmas.
during the randomised period, platelet transfusions were administered to 4.7% of patients receiving jakavi and to 4.0% of patients receiving control regimens.

kangreloori kasutamisel registreeriti tõsiseid ülitundlikkuse juhte sagedamini (0,05%) kui kontrollrühmas (0,007%).
a higher rate of serious cases of hypersensitivity were recorded with cangrelor (0.05%) than with control (0.007%).

erinevate pahaloomuliste kasvajate (v.a nahakasvajad) esinemissagedus oli etanertseptravi saanud patsientide hulgas oluliselt suurem kui kontrollrühmas.
the incidence of non-cutaneous malignancies of various types was significantly higher in patients treated with etanercept than in the control group.